Truist Securities Reiterates Buy on NovoCure, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Gregory Fraser has reiterated a Buy rating on NovoCure (NASDAQ:NVCR) and maintained a $95 price target.
June 06, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Gregory Fraser reiterated a Buy rating on NovoCure and maintained a $95 price target.
The Buy rating and maintained price target by Truist Securities analyst Gregory Fraser indicate a positive outlook for NovoCure's stock. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100